ASUS: Abatacept in Seronegative Undifferentiated arthritis Study Prospective, Single-centre, Pilot Study Assessing the Efficacy of Abatacept in Anti-CCP Negative Undifferentiated Inflammatory Arthritis.

Trial Profile

ASUS: Abatacept in Seronegative Undifferentiated arthritis Study Prospective, Single-centre, Pilot Study Assessing the Efficacy of Abatacept in Anti-CCP Negative Undifferentiated Inflammatory Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Arthritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ASUS
  • Most Recent Events

    • 01 Jan 2017 Results published in the Rheumatology
    • 21 May 2014 Accrual to Date is 105% according to United Kingdom Clinical Research Network record.
    • 10 May 2014 According to European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top